MXCT News and Press, MaxCyte Inc. From 12/19/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Although a new year tends to bring feelings of optimism, when it comes to the current market dynamics, it’s time to consider hot stocks to book profits in before 2023 arrives. At first, circumstances appeared favorable, ...

Summary Overall bearish sentiment has increased the likelihood of finding bargains in healthcare stocks. MaxCyte, Inc.'s prospects are bright while the price currently looks attractive relative to the growth potential. MaxCyte is increasing its revenue and the market is expected to ...

ROCKVILLE, Md. and SEOUL, South Korea, Dec. 04, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therape...

MaxCyte, Inc. (MXCT) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Sean Menarguez - Director of Investor Relations Douglas Doerfler - Founder, President & Chief Executive Officer Ronald Holtz - Interim Chief Financial Offic...

MaxCyte press release ( NASDAQ: MXCT ): Q3 GAAP EPS of -$0.06 beats by $0.03 . Revenue of $10.6M (+5.0% Y/Y) beats by $0.17M . 2022 Revenue Guidance We expect core business revenue in 2022 to grow approximately 30% compared to 2021. We continue to expect SP...

22% Year-Over-Year Core Business Revenue Growth in Third Quarter 2022 Reiterates 2022 Revenue Guidance ROCKVILLE, Md., Nov. 09, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technolo...

Summary Today is a great time to invest for the long run, though the market may very likely experience more volatility before once again resuming its march higher. We expect meaningful market share gains from most if not all of our investments. Returns from here will be powere...

ROCKVILLE, Md., Oct. 12, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, deve...

Summary BAMCO’s 13F portfolio value decreased from $40.75B to $31.14B this quarter. Ron Baron increased SiteOne Landscape, ASGN, and Floor & Décor Holdings while reducing Taiwan Semi, Marriott Vacations Worldwide, and PENN Entertainment. Their top five position...

Vertex Pharmaceuticals will continue to use MaxCyte’s Flow Electroporation ® technology and ExPERT ™ platform to support gene-edited cell therapy exa-cel, formerly known as CTX001™ for hemoglobinopathies ROCKVILLE, Md., Sept. 28, 2022 (GLOBE NEWSWIR...